Bamfo Jacqueline E A K, Odibo Anthony O
Obstetrics and Gynecology, London Deanery, London WC1B 5DN, UK.
J Pregnancy. 2011;2011:640715. doi: 10.1155/2011/640715. Epub 2011 Apr 13.
Fetal growth restriction (FGR) remains a leading contributor to perinatal mortality and morbidity and metabolic syndrome in later life. Recent advances in ultrasound and Doppler have elucidated several mechanisms in the evolution of the disease. However, consistent classification and characterization regarding the severity of FGR is lacking. There is no cure, and management is reliant on a structured antenatal surveillance program with timely intervention. Hitherto, the time to deliver is an enigma. In this paper, the challenges in the diagnosis and management of FGR are discussed. The biophysical profile, Doppler, biochemical and molecular technologies that may refine management are reviewed. Finally, a model pathway for the clinical management of pregnancies complicated by FGR is presented.
胎儿生长受限(FGR)仍然是围产期死亡率、发病率以及成年后代谢综合征的主要原因。超声和多普勒技术的最新进展已经阐明了该疾病发展过程中的几种机制。然而,对于FGR严重程度的一致分类和特征描述尚不存在。目前尚无治愈方法,治疗依赖于结构化的产前监测计划及及时干预。迄今为止,分娩时机仍是个谜。本文讨论了FGR诊断和治疗中的挑战。对可能改善治疗的生物物理评分、多普勒、生化和分子技术进行了综述。最后,提出了一个用于临床管理FGR合并妊娠的模型路径。